Abstract 040: Prevalence Of Dual Indications For Antihypertensive Medications And Statins In The National Health And Nutrition Survey

Introduction: Despite widespread indications for concomitant treatment of hypertension and hyperlipidemia, the proportion of the U. S population eligible for both remains unknown. Further, although fixed-dose combinations of these drugs are associated with better adherence, few are available. Hypothesis: We hypothesized a significant proportion of the population would be eligible for antihypertensive medication and a statin. Methods: Data from the National Health and Nutrition Examination Survey from 2011 to 2018 with survey weighting to represent the noninstitutionalized U.S. population ≥18 years were utilized. Prevalence of individuals with dual indications for antihypertensive and statin therapy was determined using the 2017 ACC/AHA guidelines for hypertension and the 2019 ACC/AHA guidelines for primary prevention of cardiovascular disease, respectively. Results: Sociodemographic characteristics are shown in Table 1. Among those ≥18 years, there were 88 million (33.4%) individuals with an indication for antihypertensive medication and 88.5 million (33.9%) with an indication for a statin. 64.6 million adults or 24.8% (95% CI: 23.5 to 26.2) of the population had dual indications for antihypertensive medication and a statin. Notably, 73.4% of those indicated for antihypertensive medication were also indicated a statin. Conclusions: Quarter of the U.S. adult population and nearly three-quarters of hypertensive patients are eligible for antihypertensive medication and a statin. Combining antihypertensive medications with a statin in fixed-dose combinations could reduce medication disutility and increase adherence to optimize lipid and blood pressure goals.